1. Home
  2. AKBA vs AEAQ Comparison

AKBA vs AEAQ Comparison

Compare AKBA & AEAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.95

Market Cap

343.4M

Sector

Health Care

ML Signal

N/A

AEAQ

Activate Energy Acquisition Corp. Class A Ordinary Share

N/A

Current Price

$10.08

Market Cap

312.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
AEAQ
Founded
2007
2025
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
343.4M
312.2M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
AKBA
AEAQ
Price
$0.95
$10.08
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
8.2M
27.4K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$9.87
52 Week High
$3.19
$10.10

Technical Indicators

Market Signals
Indicator
AKBA
AEAQ
Relative Strength Index (RSI) 46.52 63.76
Support Level $0.84 $9.88
Resistance Level $0.96 $10.09
Average True Range (ATR) 0.06 0.01
MACD 0.02 0.00
Stochastic Oscillator 52.22 77.78

Price Performance

Historical Comparison
AKBA
AEAQ

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share

Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: